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Acute Coronary Syndrome
CRT-99*
Ticagrelor Versus Clopidogrel in African American Patients with Stable Coronary Artery
Disease: A Randomized, Open-label, Multiple-dose, Crossover Study
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Background: The pivotal PLATelet inhibition and Patient Outcomes (PLATO)
study evaluated ticagrelor vs clopidogrel for reduction of thrombotic events in patients
with acute coronary syndrome. African Americans (AAs) have a high mortality rate
from coronary artery disease (CAD). However, their participation in clinical studies is
limited. The aim of the present study was to compare the pharmacodynamics (PD) of
ticagrelor vs clopidogrel in AAs with stable CAD.
Methods: A multicenter, randomized, open-label, crossover PD study was conducted
in aspirin (75–100mg/day) treated AA patients with stable CAD. Patients were
randomized to receive either ticagrelor (180 mg loading dose [LD] followed by 90 mg
twice-daily maintenance dose [MD] for 7–9 days) or clopidogrel (600 mg LD fol-
lowed by 75 mg once-daily MD for 7–9 days). After a 10–14 day washout period,
patients crossed over therapy. Platelet reactivity was measured with the VerifyNow
P2Y12 function assay at the following time-points: 0.5, 2 and 8h following LD and 0,
2, 8 and 12–24h following MD.
Results: A total of 34 AA patients were randomized. At all post-dose time points,
on-treatment platelet reactivity was lower for ticagrelor versus clopidogrel (Figure).
Conclusions: In AA patients with stable CAD on daily low-dose aspirin, ticagrelor
provided a faster onset and greater extent of platelet inhibition than clopidogrel.*Indicates iMPACT Trial Accepted for Oral PresentationCRT-100
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Background: There is a need for a systematic treatment protocol for patients after
resuscitation.
Methods: A systematic diagnostic approach including ECG, echocardiogram, urgent
cardiac catheterization (“STEMI-like” workﬂow), pulmonary angiography, CT scans,
pre-deﬁned laboratory ﬁndings, IABP, hypothermia and cMRI prospectively during
the last 5 years was in our cardiology department evaluated. The primary endpoint was
the Cerebral Performance Category Scale (CPCS).
Results: From January 2008 to December 2012, 212 patients were included into our
protocol. Mean age was 66.7 years, 71.2 % were male, the mean ejection fraction was
42.9 %, the mean time from ﬁrst medical contact to start of catheterization/inter-
vention was 76.6 minutes. Ventricular ﬁbrillation (VF) was observed in 99 patients
reﬂecting 46.7 %. A signiﬁcant coronary artery stenosis (deﬁned as % stenosis > 60 %)
was found in n¼130 (61.3 %) and a percutaneous coronary intervention (PCI) was
performed in 101 patients (47.6 %). An acute coronary syndrome (ACS) was diag-
nosed in 100 patients (47.2 %), 91 patients (42.9 %) had a cardiomyopathy, and
7 patients (3.3 %) had evidence for a Tako-Tsubo cardiomyopathy. Rare diagnoses
were patients with pulmonary embolism (n¼8, 3.8 %), a vitium cordis or a congenital
defect (n¼ 4, 1.9 %), a long QT syndrome (n¼ 4, 1.9 %), an early repolarization
syndrome (n¼ 2, 0.9 %), hypertrophic cardiomyopathy (n¼ 1, 0.5 %) and aortic
dissection (n¼1, 0.5 %). A mechanical recanalization of a large thrombus of the
pulmonary artery was performed in one patient. An extracardiac cause for cardiac arrest
was observed in 12 patients (5.7 %) and mostly secondary to stroke (cerebral infarction/
bleeding).
Endpoints: The survival rate was n¼76 (35.9 %), a CPCS of 1/2 was established in 67
patients (31.8 %). In patients being treated with a PCI, a signiﬁcant difference in
mortality was found for patients with TIMI ﬂow 2/3 vs 0/1 (65.4 % vs. 95.7, p< 0.05).
The difference in mortality with respect to intra-aortic balloon pumping vs. no
pumping was not statistically signiﬁcant (70.0 % vs. 63.6 %, p¼0.6). Hypothermia was
able to reduce mortality signiﬁcantly (52.7 % vs 68.2 %, p<0.05).
Conclusion: A systematic diagnostic and therapeutic algorithm using a “STEMI-like”
workﬂow which includes urgent catheterization is feasible, safe and can improve
prognosis.
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Background: In the present study we aim to evaluate major predictors of premature
coronary artery disease (PCAD) in patients aged  35 years undergoing coronary
angiography for acute coronary syndrome.
Methods: We evaluated 224 consecutive patients aged  35 years who underwent
coronary angiography at our institution between years 2003 to 2012. For each patient,
demographics, coronary risk factors such as-family history of PCAD, hypercholes-
terolemia, diabetes mellitus, hypertension, cigarette smoking, cocaine use, biochemical
proﬁle and angiographic ﬁndings were recorded. Patients were divided into two group
1) signiﬁcant CAD  50% stenosis and 2) No or Non-signiﬁcant CAD. These two
groups were compared and data was analyzed using SPSS 16.
Results: Out of 224 patients, 64 had signiﬁcant CAD and the remaining 160 had no
or non-signiﬁcant CAD. Prevalence of smoking was found to be signiﬁcantly higher in
the signiﬁcant CAD group as compared to the no or non signiﬁcant disease group
